Abstract Library

#4618 The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumours

Introduction: Colonic neuroendocrine tumours (NETs), excluding rectal NETs, are often described as relatively common and aggressive, with inferior median survival compared to other gastrointestinal (GI) primary sites. However, epidemiological databases may conflate well-differentiated NETs with poorly differentiated NECs, leading to unclear data on prevalence, clinical behaviour, and prognosis of well-differentiated colonic NETs.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Strosberg J,

Keywords: colon, neuroendocrine tumour, caecum, sigmoid, neuroendocrine neoplasm,

#4236 Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?

Introduction: Appendiceal NETs are typically detected incidentally during appendectomy. A recent study reported no cases of metachronous metastases among patients (pts) with primary tumors

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Haider M, Strosberg J,

Keywords: appendiceal net, appendix net, neuroendocrine tumor, right hemicolectomy, appendectomy,

#4234 Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors, and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occurs sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Haider M, Strosberg J,

Keywords: gastric, ppi, neuroendocrine, type 3 gastric net,

#4220 Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lutetium-DOTATATE

Introduction: 177Lutetium (Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, radiation can cause transient inflammation/swelling of tumors which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described.

Conference:

Presenting Author:

Authors: Pelle E, Al-Toubah T, El-Haddad G, Strosberg J,

Keywords: PRRT, Acute bowel ischemia, mesenteric metastasis,

#3730 Somatostatin receptor expression in lung neuroendocrine tumors – An analysis of Dotatate PET scans

Introduction: Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine (carcinoid) tumors has not been well-characterized using modern positron emission tomography (PET) imaging. Understanding the degree and uniformity of SSTR expression is important to establish the role of SSTR-targeted treatments, including peptide receptor radiotherapy (PRRT), in lung NETs.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Montilla-Soler J, El-Haddad G, Strosberg J,

Keywords: PET dotatate, cu64, ga68, lung NET, SSTR Positive,